Free Trial

Emmanuel Papadakis Analyst Performance

Analyst at Deutsche Bank Aktiengesellschaft

Emmanuel Papadakis is a stock analyst at Deutsche Bank Aktiengesellschaft, covering 7 publicly traded companies across a range of sectors. Over the past year, Emmanuel Papadakis has issued 1 stock ratings, including and buy recommendations. While full access to Emmanuel Papadakis' proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Emmanuel Papadakis' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
19 Last 8 Years
Buy Recommendations
33.33% 5 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy33.3%5 ratings
Hold53.3%8 ratings
Sell13.3%2 ratings

Out of 15 total stock ratings issued by Emmanuel Papadakis at Deutsche Bank Aktiengesellschaft, the majority (53.3%) have been Hold recommendations, followed by 33.3% Buy and 13.3% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
57.1% of companies on NASDAQ
4 companies
NYSE
28.6% of companies on NYSE
2 companies
OTCMKTS
14.3% of companies on OTCMKTS
1 company

Emmanuel Papadakis, an analyst at Deutsche Bank Aktiengesellschaft, currently covers 7 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
7 companies
100.0%

Emmanuel Papadakis of Deutsche Bank Aktiengesellschaft specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
LARGE CAP PHARMA
3 companies
42.9%
MED - BIOMED/GENE
2 companies
28.6%
PHARMACEUTICAL PREPARATIONS
2 companies
28.6%

Emmanuel Papadakis' Ratings History at Deutsche Bank Aktiengesellschaft

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Sanofi stock logo
SNY
Sanofi
9/2/2025Upgrade$49.48Buy